Immunotherapy in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and Ipilimumab

Condition:   Head and Neck Squamous Cell Carcinoma
Interventions:   Drug: Nivolumab;   Drug: Ipilimumab
Sponsor:   Gustave Roussy, Cancer Campus, Grand Paris
Not yet recruiting

http://ift.tt/2G9t4iM